MoneyWorks4Me

Venus Remedies - Quaterly Results

26 May 2025 Evaluate
The Revenue for the quarter ended  March 2025 of Rs. 1940.40 millions grew by 10.78 % from Rs. 1751.60 millions.The Company has registered profit of Rs. 147.90  millions for the quarter ended March 2025, a growth of 18.23%  over Rs. 125.10 millions millions achieved in the corresponding quarter of last year.OP of the company witnessed a marginal growth to 293.20 millions from 251.90 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1940.40 1751.60 10.78 6394.60 5752.10 11.17 6394.60 5752.10 11.17
Other Income 67.70 39.10 73.15 207.80 113.20 83.57 207.80 113.20 83.57
PBIDT 293.20 251.90 16.40 907.70 722.00 25.72 907.70 722.00 25.72
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 293.20 251.90 16.40 1006.80 722.00 39.45 1006.80 722.00 39.45
Depreciation 44.90 57.20 -21.50 216.20 255.50 -15.38 216.20 255.50 -15.38
PBT 248.30 194.70 27.53 790.60 466.50 69.47 790.60 466.50 69.47
TAX 100.40 69.60 44.25 265.10 161.50 64.15 265.10 161.50 64.15
Deferred Tax 18.30 15.80 15.82 46.50 39.30 18.32 46.50 39.30 18.32
PAT 147.90 125.10 18.23 525.50 305.00 72.30 525.50 305.00 72.30
Equity 133.70 133.70 0.00 133.70 133.70 0.00 133.70 133.70 0.00
PBIDTM(%) 15.11 14.38 5.07 14.19 12.55 13.09 14.19 12.55 13.09
Peers
Company Name CMP
Sun Pharma. Inds. 1866.00
Dr. Reddys Labs. 1172.05
Cipla 1372.25
Lupin 2092.00
Zydus Lifesciences 1137.35
View more..